Drug Trial Radar · NCT04298060
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
Last checked: Nov 19, 2026Latest source record: Jul 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
280
Planned (sponsor's estimate)
Start
Jul 2020
Primary completion
Mar 2021
Study completion Sep 2022
Sponsor
- Lead sponsor
- Ansun Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
Conditions
- Influenza Infection
- SAD-RV Infection and COVID-19
Interventions
DAS181Drug
SD (4.5mg/day), HD (9mg/day)
PlaceboDrug
Placebo 0mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of subjects who have returned to room airTime frame: 7 days
- Percent change of subjects return to baseline oxygen requirementTime frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.